By Elodie Vaz | Published on February 24, 2026 | 3 min read
Type 1 diabetes results from the autoimmune destruction of the islets of
Langerhans, clusters of cells responsible for insulin secretion. Deprived of
this key hormone in glucose homeostasis, the body loses control of blood sugar
levels. In the United States, the Centers for Disease Control and Prevention
(CDC) estimated that nearly two million people were living with the condition
in 2021. In severe cases, whole-pancreas or islet transplantation remains an
option, but the shortage of donors and the need for lifelong immunosuppression
limit its applicability.
In response to these constraints, the in vitro production of pancreatic
tissue from stem cells represents an appealing alternative. Yet a major
obstacle remains: beta cells derived in the laboratory are often immature and
secrete insulin irregularly. A study published on February 19 in Science
by researchers from the Perelman School of Medicine and the Harvard School of
Engineering and Applied Sciences proposes an original approach: integrating an
ultrathin electronic mesh directly into the growing tissue to guide its
maturation.
Orchestrating functional maturation
The team led by Professors Juan Alvarez and Jia Liu pursued a dual
objective: to understand the electrical determinants of islet cell maturation
and to harness these signals to produce fully functional tissue. “The terms
‘bionic,’ ‘cybernetic,’ ‘cyborg’ all apply to the device we created,” said
Professor Alvarez. “What we are doing is comparable to deep stimulation of the
pancreas. Just as pacemakers help the heart maintain its rhythm, controlled
electrical impulses can help pancreatic cells develop and function properly,”
he explained in a press release.
An augmented pancreas
Professor Alvarez’s laboratory, which specializes in three-dimensional
pancreatic organoids, partnered with Professor Jia Liu’s group, experts in
biomimetic electronic implants. Together, they inserted a stretchable mesh,
thinner than a human hair, between layers of cells intended to form islets.
This conductive network makes it possible to record the electrical activity of
individual cells over a two-month period.
The researchers then imposed an artificial 24-hour circadian rhythm on
the tissue’s electrical activity. This protocol builds on previous work showing
that exposing immature cells to a biological rhythm promotes their
specialization. “I like to say that this is when the cells earn their PhD,” the
scientist explained. “It is when they stop being undecided students and fully
commit to their path.”
Synchronization and secretory competence
Introducing a circadian electrical rhythm induced marked maturation of
the islet cells. After four days of stimulation, the cells continued their
activity autonomously. They secreted insulin and other hormones at the
appropriate times, with dynamics more closely resembling those observed in
vivo.
Recordings also revealed a phenomenon of intercellular synchronization.
The imposed cycles did not merely alter individual electrical behavior but
promoted collective coordination, “like a well-coordinated team.” This
synchrony could be critical for restoring a physiological glycemic response
after transplantation.
Toward intelligent implants
Two strategies are emerging. The first would consist of “activating” the
cells in vitro using the device, then implanting them without the mesh, relying
on their acquired autonomy. The second would involve maintaining the electronic
network in situ to continuously monitor and stimulate the grafted tissue,
preventing potential functional regression related to stress or disease.
Ultimately, artificial intelligence–driven control could adjust
electrical stimulation in real time. “In the future, we could have a system
that operates without human intervention,” anticipates Professor Alvarez.
By integrating electronics at the core of living tissue, this approach
redefines the boundaries of cell therapy. Although preclinical and clinical
validation remains necessary, these “cyborg” transplants outline a path toward
more readily available pancreatic substitutes, potentially less prone to
rejection and endowed with enhanced self-regulatory capacity. Beyond diabetes,
this convergence of bioengineering and regenerative medicine may pave the way
for hybrid organs in which silicon durably supports cellular physiology.
Read next: Liver, sugar, and pills: who's in
control?
About
the Author –
Elodie Vaz
Health journalist, CFPJ graduate (2023).
Élodie explores the marks diseases leave on bodies and, more broadly, on
human life. A registered nurse since 2010, she spent twelve years at patients’
bedsides before exchanging her stethoscope for a notebook. She now investigates
the links between environment and health, convinced that the vitality of life
cannot be reduced to that of humans alone. 
